Incyte's skin disease drug fails to impress in late-stage studies; shares drop
Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.
Labiotech.eu7d
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Managed Healthcare Executive9d
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...
Managed Healthcare Executive11d
Regeneron Canada Reaches New Agreement Deal for Cancer Drug Libtayo
The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...
Bristol Post15d
Lymphoma and skin cancer hazards may be heightened by tattoos of a certain size
Specifically, individuals with tattoos seem more prone to certain cancers. "For skin cancer and lymphoma, increased hazards were found for tattoos larger than the palm of a hand," the authors wrote.
BioWorld19d
Phase III cancer successes in January include Itovebi, Libtayo, Rybrevant
In January 2025, BioWorld tracked 171 phase I-III clinical trial updates, down from 212 in December. The month delivered 12 successful phase III outcomes, six of those in cancer, while two trials ...
Johns Hopkins Medicine20d
Ultraviolet Radiation
They play a major part in skin aging and wrinkling. They also cause skin cell damage that can lead to cancer. UVB. These rays are the main cause of sunburn. They tend to damage the skin's outer layers ...
Yahoo Finance21d
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
CHICAGO, February 26, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA," the "Company"), a clinical-stage biopharmaceutical company ...
Business Wire21d
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ... in Non-Small Cell Lung Cancer (NSCLC).
BioSpace21d
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
The THIO-101 study in 3L will enroll up to 48 patients with two arms: Arm 1, continuing the evaluation of THIO sequenced with Libtayo ® (cemiplimab); and ... evaluate its activity in Non-Small Cell ...
India Today22d
Vitamin D may cut skin cancer risk. Is sunscreen reducing your natural defence?
You might be blocking more than just a tan. Find out the truth that no one is talking about. Listen to Story Vitamin D may help reduce skin cancer risk and improve prognosis. Balanced sun exposure ...